BRPI0913109A2 - solução aquosa oftálmica, uso de análogos de pgf2a, e, método para aumentar a solubilidade em água e melhorar a estabilidade de análogos de pgf2a em uma solução aquosa oftálmica - Google Patents

solução aquosa oftálmica, uso de análogos de pgf2a, e, método para aumentar a solubilidade em água e melhorar a estabilidade de análogos de pgf2a em uma solução aquosa oftálmica

Info

Publication number
BRPI0913109A2
BRPI0913109A2 BRPI0913109A BRPI0913109A BRPI0913109A2 BR PI0913109 A2 BRPI0913109 A2 BR PI0913109A2 BR PI0913109 A BRPI0913109 A BR PI0913109A BR PI0913109 A BRPI0913109 A BR PI0913109A BR PI0913109 A2 BRPI0913109 A2 BR PI0913109A2
Authority
BR
Brazil
Prior art keywords
ophthalmic
solution
aqueous
pgf2a analogs
pgf2a
Prior art date
Application number
BRPI0913109A
Other languages
English (en)
Inventor
Lehmussaari Kari
Oksala Olli
Pellinen Pertti
Reunamaki Timo
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913109(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of BRPI0913109A2 publication Critical patent/BRPI0913109A2/pt
Publication of BRPI0913109B1 publication Critical patent/BRPI0913109B1/pt
Publication of BRPI0913109B8 publication Critical patent/BRPI0913109B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0913109A 2008-05-30 2009-05-28 solução aquosa oftálmica BRPI0913109B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (3)

Publication Number Publication Date
BRPI0913109A2 true BRPI0913109A2 (pt) 2017-06-20
BRPI0913109B1 BRPI0913109B1 (pt) 2019-10-22
BRPI0913109B8 BRPI0913109B8 (pt) 2021-05-25

Family

ID=39940592

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913109A BRPI0913109B8 (pt) 2008-05-30 2009-05-28 solução aquosa oftálmica

Country Status (27)

Country Link
US (3) US9999593B2 (pt)
EP (8) EP2127638A1 (pt)
JP (9) JP2011521943A (pt)
KR (5) KR101820816B1 (pt)
CN (1) CN102083413B (pt)
AR (2) AR071937A1 (pt)
AU (1) AU2009252210C1 (pt)
BR (1) BRPI0913109B8 (pt)
CA (2) CA2965185A1 (pt)
CY (2) CY1115565T1 (pt)
DK (4) DK3205334T3 (pt)
EA (1) EA023661B1 (pt)
ES (6) ES2627837T3 (pt)
GE (1) GEP20156220B (pt)
HR (4) HRP20140979T1 (pt)
HU (3) HUE033103T2 (pt)
JO (1) JO3039B1 (pt)
LT (3) LT2772249T (pt)
MX (1) MX2010012987A (pt)
MY (1) MY159463A (pt)
PL (4) PL3714877T3 (pt)
PT (4) PT2772249T (pt)
SG (1) SG191628A1 (pt)
SI (4) SI3205334T1 (pt)
TW (1) TWI432202B (pt)
UA (1) UA102257C2 (pt)
WO (1) WO2009145356A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
ES2708451T3 (es) * 2010-07-29 2019-04-09 Allergan Inc Soluciones de bimatoprost y timolol sin conservantes
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
AU2011282679A1 (en) * 2010-07-29 2013-03-07 Allergan, Inc. Preservative free bimatoprost solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2618810B1 (en) * 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
EP3103439B1 (en) 2015-06-09 2019-08-07 MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH Drippable ophthalmic bimatoprost gel
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
AU2016349833A1 (en) * 2015-11-06 2018-05-24 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
KR102115285B1 (ko) 2017-06-22 2020-05-26 연성정밀화학(주) 녹내장 치료용 점안 조성물
EP4338751B1 (en) * 2017-12-21 2025-09-03 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
TW202400133A (zh) * 2022-03-25 2024-01-01 日商坪田實驗室股份有限公司 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物
WO2024232425A1 (ja) * 2023-05-11 2024-11-14 テイカ製薬株式会社 プロスタグランジンＦ２α誘導体の含有率低下が抑制されている製品
JP7757564B1 (ja) 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
CA2273837C (en) 1996-12-09 2003-12-30 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
ES2265166T3 (es) * 1997-10-13 2007-02-01 R-Tech Ueno, Ltd. Composicion para tratamiento de hipertension intraocular o glaucoma.
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
CA2295512C (en) 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
JP2003517441A (ja) * 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
KR100791871B1 (ko) 2000-06-19 2008-01-07 산텐 세이야꾸 가부시키가이샤 방부제
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
EP1321144B1 (en) 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
AU2003248070A1 (en) 2002-07-16 2004-02-02 Hanshin Yoki Co., Ltd. Chemical container and method of manufacturing the container
EP1547599B1 (en) * 2002-09-09 2017-11-01 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20060199863A1 (en) * 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
ATE555792T1 (de) 2004-12-24 2012-05-15 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivat enthaltende produkte
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US20080269353A1 (en) * 2005-07-13 2008-10-30 Santen Pharmaceutical Co., Ltd. Preventative Composition For Ophthalmic Use
EP1916002B1 (en) 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
DE602006016628D1 (de) 2005-10-10 2010-10-14 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
EP2127638A1 (en) 2009-12-02
CY1115565T1 (el) 2017-01-04
SI3714877T1 (sl) 2022-05-31
EA201071413A1 (ru) 2011-06-30
SI2772249T1 (sl) 2017-08-31
EP4289446A2 (en) 2023-12-13
LT3714877T (lt) 2022-04-11
WO2009145356A1 (en) 2009-12-03
CN102083413A (zh) 2011-06-01
KR101650006B1 (ko) 2016-08-22
TW201000104A (en) 2010-01-01
US20180289618A1 (en) 2018-10-11
EP3714877B1 (en) 2022-01-26
EP4289446B1 (en) 2025-02-12
HRP20220361T1 (hr) 2022-05-13
UA102257C2 (uk) 2013-06-25
JP6356868B2 (ja) 2018-07-11
PT3714877T (pt) 2022-03-10
JP2011521943A (ja) 2011-07-28
MY159463A (en) 2017-01-13
EP4035656B1 (en) 2023-11-22
EP2306977A1 (en) 2011-04-13
AR071937A1 (es) 2010-07-28
US20210059931A1 (en) 2021-03-04
JP6148317B2 (ja) 2017-06-14
JP6889789B2 (ja) 2021-06-18
ES2808050T3 (es) 2021-02-25
LT2772249T (lt) 2017-09-11
PL2772249T3 (pl) 2017-10-31
EP3205334B1 (en) 2020-04-29
AR120961A2 (es) 2022-04-06
AU2009252210C1 (en) 2016-04-14
HUE049923T2 (hu) 2020-11-30
EP4512424A2 (en) 2025-02-26
PL3714877T3 (pl) 2022-05-16
AU2009252210A1 (en) 2009-12-03
AU2009252210B2 (en) 2014-10-16
JP2018154656A (ja) 2018-10-04
KR20160102319A (ko) 2016-08-29
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
JP2020073574A (ja) 2020-05-14
HRP20140979T1 (hr) 2014-11-21
KR102246598B1 (ko) 2021-04-30
KR102114401B1 (ko) 2020-05-25
US10864159B2 (en) 2020-12-15
PL2306977T3 (pl) 2015-01-30
LT3205334T (lt) 2020-09-25
HRP20200998T1 (hr) 2020-10-16
JO3039B1 (ar) 2016-09-05
KR20200057801A (ko) 2020-05-26
JP7265584B2 (ja) 2023-04-26
JP2016065095A (ja) 2016-04-28
ES2907982T3 (es) 2022-04-27
BRPI0913109B1 (pt) 2019-10-22
JP2021120412A (ja) 2021-08-19
HUE058079T2 (hu) 2022-06-28
CN102083413B (zh) 2013-11-06
ES2495316T3 (es) 2014-09-17
US20110152264A1 (en) 2011-06-23
CA2724194A1 (en) 2009-12-03
US9999593B2 (en) 2018-06-19
MX2010012987A (es) 2011-02-24
DK2306977T3 (da) 2014-09-15
PL3205334T3 (pl) 2020-11-02
ES3014089T3 (en) 2025-04-16
KR101988642B1 (ko) 2019-06-12
ES2968837T3 (es) 2024-05-14
EP4035656A1 (en) 2022-08-03
EA023661B1 (ru) 2016-06-30
HUE033103T2 (en) 2017-11-28
SG191628A1 (en) 2013-07-31
CA2965185A1 (en) 2009-12-03
KR20190067272A (ko) 2019-06-14
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
EP4512424A3 (en) 2025-03-05
KR20110011707A (ko) 2011-02-08
CY1120351T1 (el) 2019-07-10
EP2772249A1 (en) 2014-09-03
JP2014133765A (ja) 2014-07-24
EP4289446A3 (en) 2024-01-10
EP4512424B1 (en) 2026-03-18
ES2627837T8 (es) 2018-02-26
DK3714877T3 (da) 2022-02-14
HRP20170769T1 (hr) 2017-08-11
JP6649992B2 (ja) 2020-02-19
JP2023085558A (ja) 2023-06-20
JP2017178957A (ja) 2017-10-05
PT2772249T (pt) 2017-08-08
KR20180008905A (ko) 2018-01-24
DK2772249T3 (en) 2017-07-17
GEP20156220B (en) 2015-01-26
KR101820816B1 (ko) 2018-01-22
EP3205334A1 (en) 2017-08-16
JP7520285B2 (ja) 2024-07-23
JP2024079852A (ja) 2024-06-11
EP2306977B1 (en) 2014-08-13
CA2724194C (en) 2017-06-27
EP3714877A1 (en) 2020-09-30
TWI432202B (zh) 2014-04-01
PT2306977E (pt) 2014-09-22
ES2627837T3 (es) 2017-07-31
BRPI0913109B8 (pt) 2021-05-25
PT3205334T (pt) 2020-07-31

Similar Documents

Publication Publication Date Title
BRPI0913109A2 (pt) solução aquosa oftálmica, uso de análogos de pgf2a, e, método para aumentar a solubilidade em água e melhorar a estabilidade de análogos de pgf2a em uma solução aquosa oftálmica
NO2019010I1 (no) Eravasyklin eller farmasøytisk akseptable salter derav
BRPI0907829A2 (pt) Método para produzir um lente oftálmica energizável
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BRPI1011886A2 (pt) solução contendo ácido hiplocloroso e métodos do uso do mesmo.
BRPI0911126A2 (pt) Formulação aquosa estável contendo esporo
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
BRPI0919447A2 (pt) derivados do ácido 1-amino-2-ciclobutiletilborônico
DK2361256T3 (da) Cyclohexenyl-nukleinsyreanaloger
BRPI0911410A2 (pt) análogos de carba-nucleosídeo para tratamento antiviral
BRPI1010827A2 (pt) métodos para tratamento de doença usando um transferidor epimetabólico (coenzima q10)
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
EP3663193C0 (en) CURVED WING TIP
ES1075674U8 (es) Escúter de generación de burbujas para niños.
BRPI0907298A2 (pt) preparação solúvel em água, método para produzir uma preparação e uso de uma preparação
BR112013008410A2 (pt) sistema para uso em reparação tecidual
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
DK2246339T3 (da) Benzothiazepinderivater og deres anvendelse som emulgatorer for AMPA- og NMDA-receptorer
BRPI0916131A2 (pt) método de preparação de derivados do ácido hialurônico e uso de um derivado obtido pelo método
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
BR112013011997A2 (pt) "métodos para produzir uma solução aquosa concentrada de açúcar e para produzir etanol como uso de uma levedura"
BRPI0912403A2 (pt) pasta aquosa, concreto, e, métodos para preparar uma pasta aquosa e para preparar um concreto
BRPI0822849A2 (pt) Aparelho para cirurgia oftalmológica
BR112013023056A2 (pt) derivados de oxaespiro [2,5] octano e análogos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANTEN PHARMACEUTICAL CO., LTD. (JP) ; AGC INC. (J

B25G Requested change of headquarter approved

Owner name: SANTEN PHARMACEUTICAL CO., LTD. (JP) ; AGC INC. (JP)

Owner name: SANTEN PHARMACEUTICAL CO., LTD. (JP) ; AGC INC. (J

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2829 DE 25-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.